Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 1997

View Archived Issues

Spotlight on fibrinogen antagonists

Ranitidine shows no benefit in psoriasis

Anti-IgE antibody inhibits allergen-induced EAR

ET antagonists for asthma

Neuroprotection with new lipid peroxidation inhibitor from Lilly

Clinical results reported for Senetek's Kinetin

Orally active RARgamma-specific retinoid with selective skin effects

Development update on Oncolym

New therapeutic action of aspirin reported by British researchers

Milrinone analogues as novel inotropic agents

Final results of BENESTENT-II trial presented

Novel antimicrobial agents discovered by Ortho

New inhibitors of platelet aggregation from Taiwan

New MMP and TNF inhibitor from Kanebo

TNT nears clinical trials

WHO endorses HIV test

Quadrant licenses platelet technology to Pall

Zambon discovers potent and selective NEP inhibitors

U.S. clearance for Femara

Link between high blood pressure and cancer debated

Reteplase is superior to alteplase in pulmonary embolism

Gene therapy for cardiovascular diseases

HRT and cardiovascular disease in women

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...